Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer

References

• Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020;395(10242):2008–2020.
   PubMed Web of Science ®Google Scholar
• Hackert T, Klaiber U, Pausch T, et al. Fifty Years of Surgery for Pancreatic Cancer. Pancreas. 2020;49(8):1005–1013.
   PubMedGoogle Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Gemenetzis G, Groot VP, Blair AB, et al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann Surg. 2019;270(2):340–347.
   PubMed Web of Science ®Google Scholar
• Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: a Phase 2 Clinical Trial. JAMA Oncol. 2019;5(7):1020–1027.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med. 2005;353(16):1673–1684.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. N Engl J Med. 2005;353(2):123–132.
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the Treatment of Colorectal Cancer. N Engl J Med. 2007;357(20):2040–2048.
   PubMed Web of Science ®Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317–327.
   PubMed Web of Science ®Google Scholar
• Nawrocki ST, Griffin P, Kelly KR, et al. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012;21(10):1563–1573.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Cullin-RING SY. Ligases as attractive anti-cancer targets. Curr Pharm Des. 2013;19(18):3215–3225.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med. 2005;352(24):2487–2498.
   PubMed Web of Science ®Google Scholar
• Robak T, Huang H, Jin J, et al. Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. N Engl J Med. 2015;372(10):944–953.
   PubMed Web of Science ®Google Scholar
• Berndsen CE, Wolberger C. New insights into ubiquitin E3 ligase mechanism. Nat Struct Mol Biol. 2014;21(4):301–307.
   PubMed Web of Science ®Google Scholar
• Lan H, Tang Z, Jin H, et al. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells. Sci Rep. 2016;6(1):24218.
   PubMedGoogle Scholar
• Duda DM, Borg LA, Scott DC, et al. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell. 2008;134(6):995–1006.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Morgan MA, Sun Y. Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. Antioxid Redox Signal. 2014;21(17):2383–2400.
   PubMed Web of Science ®Google Scholar
• Ferris J, Espona-Fiedler M, Hamilton C, et al. Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer. Cell Death Discov. 2020;6(1):1–14.
   Google Scholar
• Brownell JE, Sintchak MD, Gavin JM, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell. 2010;37(1):102–111.
   PubMed Web of Science ®Google Scholar
• Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458(7239):732–736.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Milhollen MA, Smith PG, et al. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 2010;70(24):10310–10320.
   PubMed Web of Science ®Google Scholar
• Milhollen MA, Narayanan U, Soucy TA, et al. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res. 2011;71(8):3042–3051.
   PubMed Web of Science ®Google Scholar
• Luo Z, Yu G, Lee HW, et al. The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth. Cancer Res. 2012;72(13):3360–3371.
   PubMed Web of Science ®Google Scholar
• Gu Y, Kaufman JL, Bernal L, et al. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood J Am Soc Hematol. 2014;123(21):3269–3276.
   Google Scholar
• Irizarry RA, Hobbs B, Collin F , et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–264.
   PubMed Web of Science ®Google Scholar
• Krämer A, Green J, Pollard J, et al. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30(4):523–530.
   PubMed Web of Science ®Google Scholar
• Nabzdyk CS, Chun M, Pradhan L, et al. High throughput RNAi assay optimization using adherent cell cytometry. J Transl Med. 2011;9(1):48.
   PubMedGoogle Scholar
• Dima SO, Tanase C, Albulescu R, et al. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas. 2012;41(7):1001–1007.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
   PubMed Web of Science ®Google Scholar
• Huang Z, Wu Y, Zhou X, et al. Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncol. 2014;10(10):1795–1807.
   PubMedGoogle Scholar
• Li J-A, Song C, Rong Y, et al. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Cell Cycle Georget Tex. 2018;17(2):191–199.
   PubMed Web of Science ®Google Scholar
• Liao H, Liu XJ, Blank JL, et al. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Mol Cell Proteomics. 2011;10(11):M111–009183.
   PubMedGoogle Scholar
• Li L, Yang H, He Y, et al. Ubiquitin-specific protease USP6 regulates the stability of the c-Jun protein. Mol Cell Biol. 2018;38(2):e00320–17.
   PubMedGoogle Scholar
• Knorr K, Schneider P, Meng X, et al. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. Cell Death Differ. 2015;22(12):2133–2142.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xiong X, Jia L, et al. Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis. 2012;3(9):e386–e386.
   PubMedGoogle Scholar
• Cullinan SB, Gordan JD, Jin J, et al. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol. 2004;24(19):8477–8486.
   PubMed Web of Science ®Google Scholar
• Deng Q, Zhang J, Gao Y, et al. MLN4924 protects against bleomycin-induced pulmonary fibrosis by inhibiting the early inflammatory process. Am J Transl Res. 2017;9(4):1810.
   PubMedGoogle Scholar
• Hao R, Song Y, Li R, et al. MLN4924 protects against interleukin-17A-induced pulmonary inflammation by disrupting ACT1-mediated signaling. Am J Physiol-Lung Cell Mol Physiol. 2019;316(6):L1070–L1080.
   PubMedGoogle Scholar
• Jin J, Jing Z, Ye Z, et al. MLN4924 suppresses lipopolysaccharide‑induced proinflammatory cytokine production in neutrophils in a dose‑dependent manner. Oncol Lett. 2018;15(5):8039–8045.
   PubMedGoogle Scholar
• Andérica-Romero AC, Hernández-Damián J, Vázquez-Cervantes GI, et al. The MLN4924 inhibitor exerts a neuroprotective effect against oxidative stress injury via Nrf2 protein accumulation. Redox Biol. 2016;8:341–347.
   PubMedGoogle Scholar
• Margheritis E, Castellani B, Magotti P, et al. Bile Acid Recognition by NAPE-PLD. ACS Chem Biol. 2016;11(10):2908–2914.
   PubMed Web of Science ®Google Scholar
• Hansen HS, Diep TA. N-acylethanolamines, anandamide and food intake. Biochem Pharmacol. 2009;78(6):553–560.
   PubMedGoogle Scholar
• Berghuis P, Rajnicek AM, Morozov YM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316(5828):1212–1216.
   PubMed Web of Science ®Google Scholar
• Wang J, Okamoto Y, Tsuboi K, et al. The stimulatory effect of phosphatidylethanolamine on N-acylphosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD). Neuropharmacology. 2008;54(1):8–15.
   PubMedGoogle Scholar
• Geurts L, Everard A, Van Hul M, et al. Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota. Nat Commun. 2015;6(1):6495.
   PubMed Web of Science ®Google Scholar
• Leishman E, Mackie K, Luquet S, et al. Lipidomics profile of a NAPE-PLD KO mouse provides evidence of a broader role of this enzyme in lipid metabolism in the brain. Biochimica et biophysica acta. . 2016;1861(6):491–500.
   PubMedGoogle Scholar
• Bottemanne P, Muccioli GG, Alhouayek M. N-acylethanolamine hydrolyzing acid amidase inhibition: tools and potential therapeutic opportunities. Drug Discov Today. 2018;23(8):1520–1529.
   PubMed Web of Science ®Google Scholar
• Castellani B, Diamanti E, Pizzirani D, et al. Synthesis and characterization of the first inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD). Chem Commun. 2017;53(95):12814–12817.
   PubMedGoogle Scholar
• Mock ED, Mustafa M, Gunduz-Cinar O, et al. Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice. Nat Chem Biol. 2020;16(6):667–675.
   PubMedGoogle Scholar